Jeanny B Aragon-Ching

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 27

Top Venues

Therapeutic advances in urology

Expert review of anticancer therapy

Expert opinion on pharmacotherapy

Clinical Medicine Insights. Oncology

Inova Schar Cancer Institute

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Inova Schar Cancer Institute Sep 15 2015

United States

Clinical Program Director of Genitourinary Cancers

Publications

Jeanny B Aragon-Ching
Refining the subgroup analyses and optimal patient population in the JAVELIN Bladder 100 trial. Translational andrology and urology 13 (4) (2024)
Jeanny B Aragon-Ching
Refining the subgroup analyses and optimal patient population in the JAVELIN Bladder 100 trial. Translational andrology and urology 13 (4) (2024)
Minira Aslanova, Eun-Mi Yu, Jeanny B Aragon-Ching
The rapidly changing treatment landscape of first-line advanced urothelial cancer (aUC) or metastatic urothelial cancer (mUC). Exploration of targeted anti-tumor therapy 5 (4) (2024)
Mohammad Atiq, Elias B A Chandran, Fatima Karzai, Ravi A Madan, Jeanny B Aragon-Ching
Emerging treatment options for prostate cancer. Expert review of anticancer therapy (2023)
Thomas Powles, Se Hoon Park, Claudia Caserta, Begoña P Valderrama, Howard Gurney, Anders Ullén, Yohann Loriot, Srikala S Sridhar, Cora N Sternberg, Joaquim Bellmunt, Jeanny B Aragon-Ching, Jing Wang, Bo Huang, Robert J Laliberte, Alessandra di Pietro, Petros D Grivas
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Mohammad Atiq, Elias B A Chandran, Fatima Karzai, Ravi A Madan, Jeanny B Aragon-Ching
Emerging treatment options for prostate cancer. Expert review of anticancer therapy 23 (6) (2023)
Eun-Mi Yu, Mythri Mudireddy, Rakesh Biswas, Jeanny B Aragon-Ching
The role of switch maintenance therapy in urothelial cancers. Therapeutic advances in urology 15 (2023)
Mohammad Atiq, Elias B A Chandran, Fatima Karzai, Ravi A Madan, Jeanny B Aragon-Ching
Emerging treatment options for prostate cancer. Expert review of anticancer therapy (2023)
Jeanny B Aragon-Ching, Robert Uzzo
Multidisciplinary treatment (MDT) perspectives in renal cell carcinoma. Therapeutic advances in urology 15 (2023)
Eun-Mi Yu, Mythri Mudireddy, Rakesh Biswas, Jeanny B Aragon-Ching
The role of switch maintenance therapy in urothelial cancers. Therapeutic advances in urology 15 (2023)
Eun-Mi Yu, Min Woo Hwang, Jeanny B Aragon-Ching
Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities. Research and reports in urology 15 (2023)
Jeanny B Aragon-Ching, Robert Uzzo
Multidisciplinary treatment (MDT) perspectives in renal cell carcinoma. Therapeutic advances in urology 15 (2023)
Eun-Mi Yu, Jeanny B Aragon-Ching
Advances with androgen deprivation therapy for prostate cancer. Expert opinion on pharmacotherapy 23 (9) (2022)
Jeanny B Aragon-Ching
Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer. Future medicinal chemistry 14 (11) (2022)
Michiel S Van Der Heijden, Thomas Powles, Daniel Petrylak, Ronald de Wit, Andrea Necchi, Cora N Sternberg, Nobuaki Matsubara, Hiroyuki Nishiyama, Daniel Castellano, Syed Anwer Hussain, Aristotelis Bamias, Georgios Gakis, Jae-Lyun Lee, Scott T Tagawa, Ulka Vaishampayan, Jeanny B Aragon-Ching, Bernhard J Eigl, Rebecca R Hozak, Erik R Rasmussen, Meng Summer Xia, Ryan Rhodes, Sameera Wijayawardana, Katherine M Bell-McGuinn, Amit Aggarwal, Alexandra Drakaki
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature communications 13 (1) (2022)
Jeanny B Aragon-Ching
Pembrolizumab use in bladder cancer: a tale of two trials. Nature reviews. Urology 18 (10) (2022)
Eun-Mi Yu, Laura Linville, Matthew Rosenthal, Jeanny B Aragon-Ching
A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. Vaccines 9 (8) (2021)
Vincent Chau, Ravi A Madan, Jeanny B Aragon-Ching
Protein kinase inhibitors for the treatment of prostate cancer. Expert opinion on pharmacotherapy 22 (14) (2021)
Jeanny B Aragon-Ching
The emerging role of checkpoint inhibitors for rare genitourinary cancers. Nature reviews. Urology 18 (3) (2021)
Logan P Rhea, Jeanny B Aragon-Ching
Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer. Clinical Medicine Insights. Oncology 15 (2021)
Shruti U Gandhy, Ravi A Madan, Jeanny B Aragon-Ching
The immunotherapy revolution in genitourinary malignancies. Immunotherapy 12 (11) (2020)
Jeanny B Aragon-Ching, Ravi A Madan
Life under the CABOSUN: Cabozantinib improves quality-adjusted survival in comparison with sunitinib. Cancer 126 (24) (2020)
Alisa Erck, Jeanny B Aragon-Ching
Maintenance avelumab for metastatic urothelial cancer: a new standard of care. Cancer biology & therapy 21 (12) (2020)
Jeanny B Aragon-Ching, Robert Dreicer
Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. Expert review of anticancer therapy 20 (6) (2020)
Joelle El-Amm, Jeanny B Aragon-Ching
The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights. Oncology 13 (2019)
Antoine Finianos, Jeanny B Aragon-Ching
Zoledronic acid for the treatment of prostate cancer. Expert opinion on pharmacotherapy 20 (6) (2019)
Amanda Nizam, Jeanny B Aragon-Ching
Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care. Cancer biology & therapy 20 (1) (2018)

Jeanny B Aragon-Ching.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jeanny B Aragon-Ching